{"filing":{"accession_number":"0001628280-26-060904","cik":"0002131524","ticker":null,"company_name":"Braveheart Bio, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"bhb-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2131524/000162828026060904/bhb-20260908.htm"},"events":[{"id":31966,"run_id":29361,"accession_number":"0001628280-26-060904","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Braveheart Bio disclosed its unaudited financial results for the second quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes condensed statements of operations and comprehensive loss, balance sheets, and detailed financial metrics (R\u0026D expenses of $11.1M, G\u0026A expenses of $4.8M, net loss of $15.0M, and net loss per share of $2.51). This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial condition and cash runway (estimated to support operations into 2029).","company_name":"Braveheart Bio, Inc.","ticker":null,"filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35015,"accession_number":"0001628280-26-060904","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Braveheart Bio disclosed its unaudited financial results for the second quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes condensed statements of operations and comprehensive loss, balance sheets, and detailed financial metrics (R\u0026D expenses of $11.1M, G\u0026A expenses of $4.8M, net loss of $15.0M, and net loss per share of $2.51). This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial condition and cash runway (estimated to support operations into 2029).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:51.038080+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35015,"accession_number":"0001628280-26-060904","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Braveheart Bio disclosed its unaudited financial results for the second quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes condensed statements of operations and comprehensive loss, balance sheets, and detailed financial metrics (R\u0026D expenses of $11.1M, G\u0026A expenses of $4.8M, net loss of $15.0M, and net loss per share of $2.51). This is a standard quarterly earnings release for a clinical-stage biopharmaceutical company, material to investors assessing the company's financial condition and cash runway (estimated to support operations into 2029).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:51.038080+00:00","company_name":"Braveheart Bio, Inc.","ticker":null,"filing_date":"2026-09-08"}]}